Pinorubin (pirarubicin) / Sanofi - LARVOL DELTA

Primary sarcomatoid urothelial carcinoma of the ureter: A case report and literature review. (PubMed, Urol Case Rep) - "The patient received one cycle of pirarubicin followed by five cycles of pirarubicin plus ifosfamide and subsequent anlotinib maintenance. At 11 months, the nodes had markedly decreased; the disease remained radiographically stable at the latest follow-up."

Journal • Oncology • Sarcoma • Solid Tumor • Urothelial Cancer

MoonRISe-2, a Phase 2 Dose Expansion Within the Study of Erdafitinib Intravesical Drug Releasing System (TAR-210) for Localized Bladder Cancer: Study Design and Baseline Characteristics (AUA 2026) - P1/2 | "Funding: Johnson & Johnson.an = 53.bOther intravesical therapies included cabergoline, cretostimogene grenadenorepvec, and pirarubicin in 1 patient (1.9%) each.cn = 47.dn = 16.en = 7. Median sum of lesion size was 15 mm; 73.6% of patients had multiple (≥2) tumors. Majority of patients had multiple prior cancer-related procedures, including median of 2 TURBTs; 42.6% had prior IVES therapy, including BCG (18.5%), mitomycin C (13.0%), gemcitabine (11.1%), and epirubicin (3.7%) (Table)."

P2 data • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • FGFR

Single, early intravesical instillation of pirarubicin in the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403): a multicentre, open-label, randomised, phase 3 trial. (PubMed, Lancet Oncol) - "A single, postoperative pirarubicin instillation after radical nephroureterectomy is an efficacious treatment with manageable adverse events to reduce recurrence in patients with upper tract urothelial carcinoma."

Journal • P3 data • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in high-risk non-muscle-invasive bladder cancer (AUA 2024) - "Intensive intravesical instillation of low-dose THP for six times may be one of the treatment options in view of safety and efficacy after TURBT in patients with primary high-risk NMIBC."

Clinical • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Primary pulmonary artery synovial sarcoma: a case report. (PubMed, AME Case Rep) - "Six months post-surgery, imaging revealed local recurrence and lung metastases, and the patient received two cycles of ifosfamide, pirarubicin, and mesna chemotherapy with good tolerance. A broad base, unclear border, and atypical contrast perfusion should raise suspicion for malignancy. Definitive diagnosis relies on histopathology and molecular detection of SS18 rearrangement."

Journal • Cardiovascular • Oncology • Pain • Sarcoma • Solid Tumor • Spindle Cell Sarcoma • Synovial Sarcoma • SS18

PRIMARY MALIGNANT LYMPHOMA OF THE RENAL PELVIS : A CASE REPORT (PubMed, Hinyokika Kiyo) - "The patient received eight cycles of R-THP-COP (rituximab, pirarubicin, cyclophosphamide, vincristine and prednisolone) chemotherapy, and para-aortic lymphadenopathy regressed. As imaging findings are nonspecific and urinary cytology is usually negative, preoperative diagnosis of renal pelvic lymphoma is challenging. Nephroureterectomy can serve as both a diagnostic and therapeutic procedure, and malignant lymphoma should be considered in the differential diagnosis of renal pelvic tumors."

Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Nephrology • Non-Hodgkin’s Lymphoma • Oncology • Pain • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer • CD20 • CD79A

Real-world comparison of brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone and anthracycline-based regimens in peripheral T-cell lymphoma: A multicenter retrospective study from the Gifu Hematology Study Group. (PubMed, J Clin Exp Hematop) - "Patients received BV-CHP, CHOP, or cyclophosphamide, pirarubicin, vincristine, and prednisone (THP-COP) as first-line therapy. These findings suggest that THP-COP remains a reasonable first-line treatment option in routine clinical practice. The inferior PFS observed in patients with bone marrow involvement treated with BV-CHP should be interpreted cautiously and warrants further investigation."

Journal • Real-world evidence • Retrospective data • Hematological Disorders • Hematological Malignancies • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • TNFRSF8

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC (clinicaltrials.gov) - P3 | N=236 | Recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Clinical diagnosis and treatment of four cases of Castleman disease in children (PubMed, Zhongguo Dang Dai Er Ke Za Zhi) - "The case with abdominal pain received subsequent enteral nutrition and oral thalidomide therapy...The severe multicentric case was treated with rituximab combined with vincristine, pirarubicin, cyclophosphamide, and prednisone...The overall prognosis is favorable. Further studies are needed to determine the optimal treatment for Castleman disease complicated by gastrointestinal ulcers and severe idiopathic multicentric Castleman disease."

Journal • Classical Hodgkin Lymphoma • Fatigue • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hepatology • Hodgkin Lymphoma • Liver Failure • Lymphoma • Oncology • Pain • Rare Diseases

Intravesical pirarubicin after nephroureterectomy. (PubMed, Lancet Oncol) - No abstract available

Journal

Primary diffuse large B-cell lymphoma of the rectus abdominis muscle: a presumed primary case report and literature review. (PubMed, Front Oncol) - "The patient received 4 cycles of an attenuated R-THP-COP regimen (rituximab, pirarubicin [tetrahydropyranyl adriamycin, THP, substituted for doxorubicin to reduce cardiotoxicity], cyclophosphamide, vincristine and prednisone). In this single elderly patient, an attenuated R-THP-COP regimen was well tolerated and produced a sustained complete clinical response, suggesting that an individualised, biopsy-guided, chemotherapy-based approach may be a reasonable option for similarly localised disease in elderly patients; this observation, however, requires confirmation in larger series. This case enriches the clinical data of this rare disease and provides a reference for clinical diagnosis and treatment."

Journal • B Cell Lymphoma • Cardiovascular • Colorectal Cancer • Diffuse Large B Cell Lymphoma • Geriatric Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pain • Rare Diseases • B2M

Transcystostomal Bladder Tumor Resection in a Transgender Man After Phalloplasty. (PubMed, Asian J Endosc Surg) - "The two-stage transcystostomal approach, combining prior SPC placement, balloon tract dilation, and the modified Valdivia position, enabled safe oncological control while preserving phallic anatomy and standing voiding function. This technique offers a reproducible option for bladder tumor resection in patients with functionally inadequate transurethral access after phalloplasty."

Journal • Bladder Cancer • Oncology • Solid Tumor • Urothelial Cancer

A PRELIMINARY CLINICAL STUDY ON REDUCED-DOSE TALQUETAMAB COMBINED WITH PACE REGIMEN BRIDGE BCMA CAR-T THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA WITH MULTIPLE EXTRAMEDULLARY LESIONS (EHA 2026) - "The PACE regimen (cisplatin, pirarubicin, cyclophosphamide, and etoposide) also offers good responses in RRMM with EMLs, though its effects are short-lived...(3) Consolidation: Three patients received ASCT followed by BCMA CAR-T (4.63–6.32 × 10 ⁶ /kg) on days +3 to +7 post-transplant; other four patients received fludarabine-cyclophosphamide lymphodepletion followed by the same dose of BCMA CAR-T...All patients remain under follow-up. Summary/Conclusion The reduced-dose Talquetamab bridging BCMA CAR-T effectively improves the outcome of RRMM patients with multiple high-risk features, especially those who with multiple EMLs."

CAR T-Cell Therapy • Clinical • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Plasmacytoma • Respiratory Diseases • GPRC5D

Anlotinib combined with neoadjuvant chemotherapy for HR+/HER2- breast cancer (ACNTBC): a prospective, single-arm, single-center phase II clinical study with real-world validation. (PubMed, Signal Transduct Target Ther) - P2 | "Enrolled patients received 5 cycles of anlotinib (12 mg qd, d1‒14; q3w) plus 6 cycles of nab-paclitaxel (200 mg/m2, q3w), pirarubicin (50 mg/m2, q3w), and cyclophosphamide (500 mg/m2, q3w). Supporting evidence from an exploratory inverse probability of treatment weighting (IPTW) analysis using a real-world cohort receiving chemotherapy alone indicated a potential benefit of the combination over chemotherapy alone. In conclusion, neoadjuvant anlotinib plus chemotherapy demonstrates promising efficacy and manageable safety in HR+/HER2- breast cancer with a high Ki-67 index."

Journal • P2 data • Real-world evidence • Breast Cancer • Cardiovascular • Hematological Disorders • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Hypertension • Oncology • Pain • Renal Disease • Solid Tumor • HER-2 • KDR

The influence of structural diversity in polymer-based nanomedicines on anti-cancer efficacy. (PubMed, J Control Release) - "Despite comparable drug loading, the carriers showed markedly different anticancer efficacy, with optimized structures achieving superior tumor growth inhibition and improved intratumoral penetration. These results provide direct evidence that polymer structure is a key determinant of treatment outcome and offer guidance for designing more effective polymer-pirarubicin conjugates for anticancer therapy."

Journal • Oncology

Clinically actionable TURBT-derived bladder cancer organoid pharmacotyping as a predictor of postoperative outcomes in a prospective multicenter study. (ASCO 2026) - P | "IC50 values spanned submicromolar medians for anthracyclines/pirarubicin (pirarubicin 0.080 µM; doxorubicin 0.540 µM; epirubicin 0.508 µM) to higher micromolar medians for platinum/antimetabolites (cisplatin 20.245 µM; gemcitabine 16.913 µM; methotrexate 61.205 µM), with gemcitabine showing the widest range (0.004–369.500 µM). This multicenter TURBT-derived bladder cancer PDO study establishes a clinically actionable pharmacotyping workflow. PDOs can be generated from routine specimens, capture marked inter-patient drug-response heterogeneity, and provide drug-specific sensitivity tiers that align with postoperative outcomes with high specificity for identifying potentially ineffective therapy. These data support prospective validation of PDO-guided regimen selection to reduce futile treatment and individualize postoperative bladder cancer care."

Clinical • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • TP63

A Retrospective Follow-up Study on the Effects of Different Intravesical Treatments on Recurrence Control and Quality of Life in Patients With Non-Muscle-Invasive Bladder Cancer After Transurethral Resection of Bladder Tumour. (PubMed, Arch Esp Urol) - "In patients with NMIBC after TURBT, intravesical BCG was associated with better recurrence control and more favourable mid-to long-term functional and quality-of-life outcomes than pirarubicin, particularly in high-grade disease."

HEOR • Journal • Retrospective data • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Healthy birth after chemotherapy for diffuse large B-cell lymphoma with superior vena cava syndrome in late pregnancy: A case report. (PubMed, SAGE Open Med Case Rep) - "The initial treatment consisted of a combination of rituximab, cyclophosphamide, pirarubicin, vincristine, and dexamethasone and etoposide chemotherapy. Notably, NKG2C+ natural killer cells-potentially representing antitumor reactive lymphocytes-were detected during the initial treatment but eventually became undetectable. Overall, the patient achieved a satisfactory and notable treatment outcome."

Journal • B Cell Lymphoma • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pulmonary Disease • Transplantation

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC (clinicaltrials.gov) - P3 | N=236 | Not yet recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Initiation date: Mar 2026 ➔ Jun 2026

Trial initiation date • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Cardiac monitoring in adolescent and young adult cancer patients treated with anthracyclines: a longitudinal descriptive study. (PubMed, Support Care Cancer) - "Echocardiographic monitoring before, during, and after anthracycline therapy in Japanese AYA patients is suboptimal, with marked disparities by age, sex, cancer type, anthracycline agent, and treatment setting. Targeted quality-improvement initiatives and harmonized risk-stratified monitoring pathways are needed to prevent unrecognized anthracycline-related cardiomyopathy in this vulnerable population."

Journal • Breast Cancer • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

HIV-related bladder cancer: A ten-year experience. (PubMed, Int J STD AIDS) - "Adjuvant immunotherapy (tislelizumab) combined with chemotherapy (gemcitabine and cisplatin) was used in six patients after radical cystectomy. Limited data preliminarily suggest that intravesical chemotherapy with pirarubicin and adjuvant immunotherapy combined with chemotherapy may be safe and effective options for PLWH with bladder cancer; however, these observations require validation in larger studies. PLWH with muscle-invasive bladder cancer appear to have poorer cancer-specific survival."

Journal • Bladder Cancer • Genito-urinary Cancer • Human Immunodeficiency Virus • Infectious Disease • Oncology • Solid Tumor

Comparative Effectiveness of Intravesical Chemotherapy Agents versus Bacillus Calmette-Guérin in High-Risk Non-Muscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis (AUA 2026) - " Following PRISMA guidelines, we searched PubMed, Embase, and the Cochrane Library for randomized controlled trials and cohort studies with ≥6 months of follow-up comparing BCG with intravesical chemotherapy (pirarubicin [THP], epirubicin [EPI], mitomycin C [MMC], gemcitabine [GEM], and gemcitabine plus docetaxel [GEM+DOC]) in BCG-naive patients. Intravesical chemotherapy may be as effective as BCG in reducing recurrence in high-risk NMIBC, with GEM+DOC showing potential superiority. However, high heterogeneity and limited subgroup data warrant further large-scale trials. Treatment decisions should consider patient-specific factors, toxicity and resource availability."

HEOR • Retrospective data • Review • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Antitumor efficacy and reduced systemic toxicity of palmitic acid-modified pirarubicin nanoparticles in mice. (PubMed, Cancer Chemother Pharmacol) - "Pal-THP nanoparticles altered the in vivo fate of THP through tumor accumulation and tumor-localized conversion to free THP. This resulted in effective tumor suppression and a significant reduction in toxicity compared to THP in mice. Thus, this formulation strategy represents a promising approach for improving the therapeutic index of chemotherapy using THP and other anthracyclines."

Journal • Preclinical • Colon Cancer • Colorectal Cancer • Oncology

pH responsive delivery of gemcitabine/pirarubicin co-loaded biodegradable polymeric nanoparticles for synergistic anti-cancer therapy (AACR 2024) - "Additionally, apoptotic studies revealed significant enhancement in synergistic activity in the case of PIRA/GEM co-loaded Nps in comparison to conventional free drug formulations. In conclusion, this nano-formulation demonstrated excellent anti-cancer activity against breast cancer cells therefore it may be used as a potential candidate for therapeutic use."

Breast Cancer • Oncology • Solid Tumor

Efficacy and Safety of Thermosensitive Hydrogel Combined with Pirarubicin via TACE for Hepatocellular Carcinoma: A Pilot Study. (PubMed, Cancer Manag Res) - "Tepoxin combined with pirarubicin TACE is technically feasible and well-tolerated in HCC patients, showing early anti-tumor activity. Larger, well-designed studies are needed to confirm its efficacy and safety."

Journal • Hepatocellular Cancer • Oncology • Pain • Solid Tumor